Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Coherus Oncology, Inc. - Common Stock
(NQ:
CHRS
)
1.370
-0.050 (-3.52%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Coherus Oncology, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Earnings Scheduled For November 6, 2025
↗
November 06, 2025
Via
Benzinga
Coherus BioSciences's Earnings Outlook
↗
November 05, 2025
Via
Benzinga
4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals
↗
October 10, 2025
4 biotech stocks—ALDX, ALEC, BDTX, CHRS—show strong week-on-week momentum ranking gains and improving technical indicators.
Via
Benzinga
This Brinker International Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
↗
September 04, 2025
Via
Benzinga
Coherus (CHRS) Q2 Revenue Jumps 10%
↗
August 07, 2025
Via
The Motley Fool
Earnings Scheduled For August 7, 2025
↗
August 07, 2025
Via
Benzinga
Insights Ahead: Coherus BioSciences's Quarterly Earnings
↗
August 06, 2025
Via
Benzinga
Earnings Scheduled For May 12, 2025
↗
May 12, 2025
Via
Benzinga
Earnings Preview: Coherus BioSciences
↗
May 09, 2025
Via
Benzinga
Recap: Coherus BioSciences Q4 Earnings
↗
March 13, 2024
Via
Benzinga
Which stocks are moving after the closing bell on Friday?
↗
July 04, 2025
The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today.
Via
Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
July 03, 2025
Via
Benzinga
Top movers in Friday's after hours session
↗
May 23, 2025
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Via
Chartmill
Earnings Preview For Coherus BioSciences
↗
March 12, 2024
Via
Benzinga
Which stocks are moving before the opening bell on Tuesday?
↗
May 13, 2025
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
Via
Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
May 13, 2025
Via
Benzinga
Which stocks are moving after the closing bell on Wednesday?
↗
April 16, 2025
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
Via
Chartmill
Earnings Scheduled For March 10, 2025
↗
March 10, 2025
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
December 03, 2024
Via
Benzinga
Why Is Coherus BioSciences Stock Trading Higher On Tuesday?
↗
December 03, 2024
Coherus sells Udenyca franchise for up to $558.4 million, shifts focus to immuno-oncology R&D, and plans clinical trials in hepatocellular carcinoma and NSCLC.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
November 07, 2024
Via
Benzinga
CHRS Stock Earnings: Coherus BioSciences Beats EPS, Beats Revenue for Q2 2024
↗
August 08, 2024
CHRS stock results show that Coherus BioSciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary
↗
June 30, 2024
Shanghai Henlius Biotech agreed to be a wholly owned subsidiary of Fosun in a $690 million deal that values the company at $1.7 billion. Meanwhile, Suzhou Ascentage Pharma filed to list in the US to...
Via
Talk Markets
CHRS Stock Earnings: Coherus BioSciences Misses EPS, Misses Revenue for Q1 2024
↗
May 09, 2024
CHRS stock results show that Coherus BioSciences missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Why Coherus Biosciences Stock Tumbled on Thursday
↗
March 14, 2024
The company fell well short of expectations for its fourth quarter.
Via
The Motley Fool
Earnings Scheduled For March 13, 2024
↗
March 13, 2024
Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share on revenue of $8.10 million.
Via
Benzinga
Why Coherus BioSciences Stock Jumped Today
↗
February 06, 2024
As promised, Coherus is using the proceeds of a recent divestiture to pay down debt and reduce interest expenses.
Via
The Motley Fool
Why Coherus BioSciences Stock Is Sinking Today
↗
January 23, 2024
The positive reaction to Coherus' sale of its ophthalmology franchise to Sandoz didn't last long.
Via
The Motley Fool
Why Coherus Biosciences Popped Today
↗
January 22, 2024
Coherus is divesting its non-core ophthalmology franchise.
Via
The Motley Fool
Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
January 22, 2024
Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
